China Merchants Securities Co.Ltd(600999)
About Sirio Pharma Co.Ltd(300791)
Verification opinions of internal control evaluation report in 2021
China Merchants Securities Co.Ltd(600999) (hereinafter referred to as ” China Merchants Securities Co.Ltd(600999) ” and “sponsor”) as a sponsor of Sirio Pharma Co.Ltd(300791) (hereinafter referred to as ” Sirio Pharma Co.Ltd(300791) ” and “company”) issuing convertible corporate bonds to unspecified objects, in accordance with the administrative measures for securities issuance and listing sponsor business, basic norms of enterprise internal control, Shenzhen Stock Exchange gem stock listing rules and other relevant provisions, The internal control of Sirio Pharma Co.Ltd(300791) 2021 was verified, and the verification opinions are as follows: I. verification work of the recommendation institution
By reviewing the relevant systems of Sirio Pharma Co.Ltd(300791) internal control, reviewing the Sirio Pharma Co.Ltd(300791) information disclosure documents, communicating with the company’s internal auditors and senior managers, and combining with the daily continuous supervision work, the sponsor verified the internal control evaluation report issued by the company’s board of directors on the basis of reasonable evaluation of the integrity, rationality and effectiveness of the company’s internal control. 2、 Sirio Pharma Co.Ltd(300791) internal control evaluation conclusion
According to the identification of major defects in the company’s internal control over financial reporting, there are no major defects in the internal control over financial reporting on the benchmark date of the internal control evaluation report. The board of Directors believes that the company has maintained effective internal control over financial reporting in all major aspects in accordance with the requirements of the enterprise’s internal control standard system and relevant regulations. According to the identification of major defects in the company’s internal control over non-financial reports, the company found no major defects in the company’s internal control over non-financial reports on the benchmark date of the internal control evaluation report.
There are no factors affecting the evaluation conclusion of the effectiveness of internal control from the base date of the internal control evaluation report to the date of issuance of the internal control evaluation report. 3、 Verification opinions of the recommendation institution
After verification, the sponsor believes that: Sirio Pharma Co.Ltd(300791) has established a relatively sound corporate governance structure, and the current internal control system and implementation comply with the provisions of relevant laws, regulations and normative documents such as the Listing Rules of gem shares of Shenzhen Stock Exchange; The company has maintained effective internal control over financial reporting in all major aspects in accordance with the requirements of the enterprise internal control standard system and relevant regulations; The recommendation institution has no objection to the 2021 internal control evaluation report issued by the board of directors of the company.
(no text below)
(there is no text on this page, which is the signature and seal page of China Merchants Securities Co.Ltd(600999) verification opinions on Sirio Pharma Co.Ltd(300791) 2021 annual internal control evaluation report)
Sponsor representative:
Liu Xingde, Shi Zhihua
China Merchants Securities Co.Ltd(600999) 2022
